Search

Your search keyword '"A, Cohen-Billiemaz"' showing total 2 results
Start Over Author "A, Cohen-Billiemaz"
2 results on '"A, Cohen-Billiemaz"'

1. [Comparative study of LpAI lipoparticles, HDL cholesterol and apolipoprotein AI in a control population, in a group of subjects with coronary diseases, and in a group of subjects with angiographically normal coronary vessels]

Author

J P, Ardissone, A, Cohen-Billiemaz, M, Heim, J M, Gulian, J P, Giordanella, M, Bory, and M, Charrel

Subjects
Adult, Male, Immunodiffusion, Apolipoprotein A-I, Cholesterol, HDL, Humans, Coronary Disease, Female, Middle Aged, Coronary Angiography, Aged
Abstract

A new method for directly measuring LpAI lipoparticles containing apolipoprotein AI, but not apolipoprotein AII, is now disponible for laboratories. Concentrations of LpAI were measured in serum from 158 presumably healthy normolipidemic subjects (72 male, 86 female), for the age group 30-60 years. Concentrations of LpAI were also measured in subjects with angiographically defined coronary artery disease (coro+) and without angiographically defined coronary artery disease (coro-). After comparison of the groups, lipoprotein particle LpAI did not appear to be a better discriminative marker than HDL cholesterol or apolipoprotein AI for atherogen risk.

Published
1992

2. [Comparative study of LpAI lipoparticles, HDL cholesterol and apolipoprotein AI in a control population, in a group of subjects with coronary diseases, and in a group of subjects with angiographically normal coronary vessels].

Author

Ardissone JP, Cohen-Billiemaz A, Heim M, Gulian JM, Giordanella JP, Bory M, and Charrel M

Subjects
Adult, Aged, Coronary Angiography, Coronary Disease diagnostic imaging, Female, Humans, Immunodiffusion methods, Male, Middle Aged, Apolipoprotein A-I chemistry, Cholesterol, HDL blood, Coronary Disease blood
Abstract

A new method for directly measuring LpAI lipoparticles containing apolipoprotein AI, but not apolipoprotein AII, is now disponible for laboratories. Concentrations of LpAI were measured in serum from 158 presumably healthy normolipidemic subjects (72 male, 86 female), for the age group 30-60 years. Concentrations of LpAI were also measured in subjects with angiographically defined coronary artery disease (coro+) and without angiographically defined coronary artery disease (coro-). After comparison of the groups, lipoprotein particle LpAI did not appear to be a better discriminative marker than HDL cholesterol or apolipoprotein AI for atherogen risk.

Published
1992

Catalog

Books, media, physical & digital resources
See catalog results